[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100527820":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":75,"collaborators":19,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":19,"enrollmentInfo":86,"targetDuration":19,"studyType":89,"phases":90,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":43,"whyStopped":19,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Centre Francois Baclesse","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"HRD tests","To determine HRD status on the tumor, 2 different tests will be used concomitantly",[12],"Genetic: tests to determine HRD status",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"GENETIC","tests to determine HRD status","Test Giscar AND test myChoice will be performed.\n\nIf one or two tests identifies a HRD status :\n\na PARP inhibitor treatment may be initiated according to current recommendations",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Raphaël LEMAN, PhD","CONTACT","33231455050","r.leman@baclesse.unicancer.fr",[27,42,53,64],{"facility":28,"status":29,"city":30,"state":19,"zip":19,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"Chu Amiens","NOT_YET_RECRUITING","Amiens","France","FR",{"type":34,"coordinates":35},"Point",[36,37],2.3,49.9,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":19,"phoneExt":19,"email":19},"Pierrick THERET, MD",{"facility":5,"status":43,"city":44,"state":19,"zip":19,"country":31,"countryCode":32,"cosmosGeoPoint":45,"geoPoint":49,"contacts":50},"RECRUITING","Caen",{"type":34,"coordinates":46},[47,48],-0.35912,49.18585,{"lat":48,"lon":47},[51],{"name":52,"role":23,"phone":19,"phoneExt":19,"email":19},"François CHERIFI, MD",{"facility":54,"status":43,"city":55,"state":19,"zip":19,"country":31,"countryCode":32,"cosmosGeoPoint":56,"geoPoint":60,"contacts":61},"Centre Oscar Lambret","Lille",{"type":34,"coordinates":57},[58,59],3.05512,50.63391,{"lat":59,"lon":58},[62],{"name":63,"role":23,"phone":19,"phoneExt":19,"email":19},"Camille PASQUESOONE, MD",{"facility":65,"status":43,"city":66,"state":19,"zip":19,"country":31,"countryCode":32,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Centre Henri Becquerel","Rouen",{"type":34,"coordinates":68},[69,70],1.09932,49.44313,{"lat":70,"lon":69},[73],{"name":74,"role":23,"phone":19,"phoneExt":19,"email":19},"Marianne LEHEURTEUR, MD",{"type":76,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100527820","phase-2-hrd-tests-for-ovarian-cancer-100527820",false,"NCT06152731","HRD Tests for Ovarian cancER","HERO","Inclusion Criteria:\n\n* Patient aged 18-year or more\n* Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer\n* Newly diagnosed advanced (International Federation of Gynecology and Obstetrics \\[FIGO\\] stage III or IV) ovarian carcinoma, candidate to a first line platinum-based chemotherapy\n* Tumor tissue must be available for HRD analyses (FFPE tissue block) and\n\n  * Collected if possible during the initial surgery or the initial biopsy (before chemotherapy)\n  * With sufficient tumour surface area (\\> 25 mm²), with a final cellularity of at least 20%\n* Patient affiliated to an appropriate social security system\n* Patient signed consent form before any trial related activities\n\nExclusion Criteria:\n\n* Recurrent high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer\n* Non epithelial or borderline ovarian cancer\n* Other tumor, for which the treatment may interfere with the ovarian cancer treatment and\u002For that may have a major impact on prognosis\n* Exclusive palliative setting\n* Patient deprived of liberty or placed under the authority of a tutor","FEMALE","18 Years",{"count":87,"type":88},88,"ESTIMATED","INTERVENTIONAL",[91],"PHASE2","The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy.\n\nTo determine HRD status, 2 separate tests will be performed in the study:\n\n1. Giscar assay : developed by the sponsor\n2. myChoice assay\n\nIf one or two tests identifies a HRD status :\n\na PARP inhibitor treatment may be initiated according to current recommendations",[94],"Ovarian Cancer",[96,97,98,99],"HRD (Homologous Recombination Deficient)","GIScar","myChoice","platinum chemotherapy","2025-09-16",{"date":102,"type":103},"2025-09-17","ACTUAL",{"date":105,"type":103},"2024-02-15",{"date":107,"type":88},"2031-06",{"name":5,"class":6},4]